BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer

被引:62
|
作者
Niell, BL
Rennert, G
Bonner, JD
Almog, R
Tomsho, LP
Gruber, SB
机构
[1] Univ Michigan, Sch Med, Dept Internal Med, Div Med & Mol Genet, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI USA
[3] Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI USA
[4] Carmel Hosp, Dept Community Med & Epidemiol, Haifa, Israel
[5] Tech Fac Med, Haifa, Israel
[6] Natl Canc Control Ctr, Clalit Hlth Serv, Haifa, Israel
来源
关键词
D O I
10.1093/jnci/djh008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Mutations in BRCA1 and/or BRCA2 (BRCA1/2) profoundly increase the risks of breast and ovarian cancers, but it is unclear whether mutations in these genes increase the risk of colorectal cancer. We investigated BRCA1/2 founder mutations and a family history of breast cancer as potential risk factors for colorectal cancer. Methods: In the population-based Molecular Epidemiology of Colorectal Cancer study in northern Israel, 1422 case patients with incident colorectal cancer, diagnosed between March 31, 1998, and December 31, 2002, and 1566 control subjects without colorectal cancer were genotyped for the BRCA1 187delAG, BRCA1 5385insC, and BRCA2 6174delT founder mutations. Genotypes and interview data from all case patients and control subjects and from only those of Ashkenazi Jewish descent (1002 case patients and 1038 control subjects) were used to calculate odds ratios [ORs] from logistic regression. Results: Twenty-four (2.4%) case patients and 20 (1.9%) control subjects carried one of the three mutations (OR = 1.24, 95% confidence interval [CI] = 0.68 to 2.26). A family history of breast cancer in a female relative was not associated with an increased risk of colorectal cancer, even after adjustment for the presence of a BRCA founder mutation (OR = 1.03, 95% CI = 0.75 to 1.41). Conclusions: Although weak associations cannot be excluded, Ashkenazi BRCA founder mutations do not confer a strongly elevated risk of colorectal cancer. Similarly, a family history of breast cancer does not appear to be a strong risk factor for colorectal cancer in this population.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 50 条
  • [21] Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families
    Tonin, PN
    Mes-Masson, AM
    Futreal, PA
    Morgan, K
    Mahon, M
    Foulkes, WD
    Cole, DEC
    Provencher, D
    Ghadirian, P
    Narod, SA
    AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (05) : 1341 - 1351
  • [22] Citywide population genetic screening for BRCA1/ BRCA2 founder mutations
    Rumyantsev, Konstantin
    Bodunova, Natalia
    Danishevich, Anastasia
    Kvetenadze, Gurami
    Khatkov, Igor
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 304 - 305
  • [23] BRCA1 and BRCA2 founder mutations in Spanish and Mexican populations.
    Alvarez-Franco, M
    Llori, G
    Gerson, R
    Bale, AE
    AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) : 268 - 268
  • [24] Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations
    Lu Yao
    Jie Sun
    Juan Zhang
    Yingjian He
    Tao Ouyang
    Jinfeng Li
    Tianfeng Wang
    Zhaoqing Fan
    Tie Fan
    Benyao Lin
    Yuntao Xie
    Breast Cancer Research and Treatment, 2016, 156 : 441 - 445
  • [25] Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations
    Yao, Lu
    Sun, Jie
    Zhang, Juan
    He, Yingjian
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xie, Yuntao
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (03) : 441 - 445
  • [26] Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations
    Stephanie Kearton
    Karen Wills
    Michael Bunting
    Penny Blomfield
    Paul A. James
    Jo Burke
    Familial Cancer, 2018, 17 : 333 - 344
  • [27] Pregnancy and breast cancer risk in women with BRCA1 or BRCA2 mutations
    Carol Lovegrove
    Nature Clinical Practice Oncology, 2006, 3 (1): : 9 - 9
  • [28] Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations
    Kearton, Stephanie
    Wills, Karen
    Bunting, Michael
    Blomfield, Penny
    James, Paul A.
    Burke, Jo
    FAMILIAL CANCER, 2018, 17 (03) : 333 - 344
  • [29] Relevant risk for women with BRCA1 and BRCA2 mutations
    Furnival, Colin
    ANZ JOURNAL OF SURGERY, 2007, 77 (05) : 309 - 309
  • [30] Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.
    Naseem, Madiha
    Xiu, Joanne
    Salem, Mohamed E.
    Goldberg, Richard M.
    Vanderwalde, Ari M.
    Grothey, Axel
    Philip, Philip Agop
    Seeber, Andreas
    Puccini, Alberto
    Tokunaga, Ryuma
    Battaglin, Francesca
    Berger, Martin D.
    Barzi, Afsaneh
    Hanna, Diana L.
    Zhang, Wu
    Hwang, Jimmy J.
    Shields, Anthony Frank
    Marshall, John
    Korn, Wolfgang Michael
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)